Patricia Harnden

Author PubWeight™ 43.56‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Spectrum of phosphatidylinositol 3-kinase pathway gene alterations in bladder cancer. Clin Cancer Res 2009 3.70
2 Genome-wide association study of renal cell carcinoma identifies two susceptibility loci on 2p21 and 11q13.3. Nat Genet 2010 2.96
3 Genetic and epigenetic analysis of von Hippel-Lindau (VHL) gene alterations and relationship with clinical variables in sporadic renal cancer. Cancer Res 2006 2.87
4 Proteomic changes in renal cancer and co-ordinate demonstration of both the glycolytic and mitochondrial aspects of the Warburg effect. Proteomics 2003 2.17
5 DNA double strand break repair in human bladder cancer is error prone and involves microhomology-associated end-joining. Nucleic Acids Res 2004 1.67
6 Analysis of VHL Gene Alterations and their Relationship to Clinical Parameters in Sporadic Conventional Renal Cell Carcinoma. Clin Cancer Res 2009 1.49
7 MRE11 expression is predictive of cause-specific survival following radical radiotherapy for muscle-invasive bladder cancer. Cancer Res 2010 1.44
8 Development and validation of a novel protein extraction methodology for quantitation of protein expression in formalin-fixed paraffin-embedded tissues using western blotting. J Pathol 2009 1.38
9 A genome-wide association study identifies a novel susceptibility locus for renal cell carcinoma on 12p11.23. Hum Mol Genet 2011 1.34
10 Sonic hedgehog regulates prostatic growth and epithelial differentiation. Dev Biol 2003 1.32
11 Mutation analysis of the 8p candidate tumour suppressor genes DBC2 (RHOBTB2) and LZTS1 in bladder cancer. Cancer Lett 2004 1.23
12 Mining the archival formalin-fixed paraffin-embedded tissue proteome: opportunities and challenges. Mol Biosyst 2008 1.18
13 Uroplakin gene expression in normal human tissues and locally advanced bladder cancer. J Pathol 2003 1.16
14 Urinary biomarker profiling in transitional cell carcinoma. Int J Cancer 2006 1.12
15 Laser capture microdissection and two-dimensional polyacrylamide gel electrophoresis: evaluation of tissue preparation and sample limitations. Am J Pathol 2002 1.10
16 Proteomic analysis of primary cell lines identifies protein changes present in renal cell carcinoma. Proteomics 2006 1.10
17 Proteomic analysis of formalin-fixed paraffin-embedded renal tissue samples by label-free MS: assessment of overall technical variability and the impact of block age. Proteomics Clin Appl 2013 1.08
18 Initial development and validation of a novel extraction method for quantitative mining of the formalin-fixed, paraffin-embedded tissue proteome for biomarker investigations. J Proteome Res 2010 1.07
19 APE1 and XRCC1 protein expression levels predict cancer-specific survival following radical radiotherapy in bladder cancer. Clin Cancer Res 2005 1.03
20 Comprehensive analysis of CDKN2A status in microdissected urothelial cell carcinoma reveals potential haploinsufficiency, a high frequency of homozygous co-deletion and associations with clinical phenotype. Clin Cancer Res 2005 0.98
21 Intrinsic chemotherapy resistance to the tubulin-binding antimitotic agents in renal cell carcinoma. Int J Cancer 2005 0.96
22 Prognostic factors in renal cell carcinoma: association of preoperative sodium concentration with survival. Clin Cancer Res 2008 0.96
23 Proteomic identification of a role for the von Hippel Lindau tumour suppressor in changes in the expression of mitochondrial proteins and septin 2 in renal cell carcinoma. Proteomics 2006 0.92
24 Towards defining roles and relationships for tenascin-C and TGFbeta-1 in the normal and neoplastic urinary bladder. J Pathol 2002 0.90
25 Impact of pre-analytical factors on the proteomic analysis of formalin-fixed paraffin-embedded tissue. Proteomics Clin Appl 2013 0.89
26 Proteomic identification of differentially expressed plasma membrane proteins in renal cell carcinoma by stable isotope labelling of a von Hippel-Lindau transfectant cell line model. Proteomics 2009 0.89
27 Metastatic castrate-resistant prostate cancer with a late, complete and durable response to docetaxel chemotherapy: a case report. J Med Case Rep 2014 0.89
28 Key clinical issues in renal cancer: a challenge for proteomics. World J Urol 2007 0.87
29 Serological and proteomic evaluation of antibody responses in the identification of tumor antigens in renal cell carcinoma. Proteomics 2003 0.86
30 Papillary and muscle invasive bladder tumors with distinct genomic stability profiles have different DNA repair fidelity and KU DNA-binding activities. Genes Chromosomes Cancer 2009 0.84
31 Cytokine-modified Mycobacterium smegmatis as a novel anticancer immunotherapy. Int J Cancer 2004 0.83
32 Resistance to the tubulin-binding agents in renal cell carcinoma: no mutations in the class I beta-tubulin gene but changes in tubulin isotype protein expression. Clin Cancer Res 2005 0.82
33 Determination of the consequences of VHL mutations on VHL transcripts in renal cell carcinoma. Int J Oncol 2012 0.81
34 Identification of genes up-regulated in urothelial tumors: the 67-kd laminin receptor and tumor-associated trypsin inhibitor. Am J Pathol 2003 0.78
35 VHL-dependent regulation of a β-dystroglycan glycoform and glycogene expression in renal cancer. Int J Oncol 2013 0.76
36 A practical application of analysing weighted kappa for panels of experts and EQA schemes in pathology. J Clin Pathol 2011 0.75
37 Measuring interobserver variation in a pathology EQA scheme using weighted κ for multiple readers. J Clin Pathol 2011 0.75
38 The feasibility of establishing a programme of adjuvant autologous vaccination for renal cell carcinoma. BJU Int 2008 0.75